This article is more than 5 years old. Information may no longer be current.

Extravan gets ‘approvable’ letter from FDA

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

FORT WORTH, Texas — A fixed combination glaucoma drug is one step closer to receiving U.S. regulatory approval, according to Alcon, the product’s manufacturer.

Alcon announced that the Food and Drug Administration has issued an “approvable” letter for Extravan ophthalmic solution for the treatment of glaucoma. Extravan solution is a fixed combination of travoprost 0.004% and timolol 0.5%.

“We will be meeting with the FDA as soon as possible to clarify what additional steps may be required to gain final approval to market Extravan,” Scott Krueger, MD, Alcon's vice president of regulatory affairs, said in a press release.